Alembic Ltd has announced that the acquisition of the entire non-oncology formulation business of Dabur Pharma Ltd. has been completed. The Company now has full rights to market the 24 brands, which came as part of this acquisition. Most brands are in the high growth lifestyle therapeutic segments of cardiology, diabetology and gynaecology.

The Company has created a new Marketing arm named 'Summit' to cater to the needs of these speciality segments of customers. The company is already the largest player in the Macrolides (anti-infective) segment of drugs in India and is now set to increase market share in the lifestyle segment.

The total consideration for the acquisition is Rs 159 crore. The acquired business posted sales of about Rs 75 crore for the financial year ending March 31, 2007 in Dabur Pharma.

Commenting on the integration, Chirayu Amin, chairman and managing director of the company said, "With this acquisition, we now have a ready product-mix as well as experienced marketing people in the lifestyle therapeutic segment. Alembic already enjoys a strong marketing network in India, and with the new products and people on board, we will further increase our reach. Alembic is constantly striving for inorganic and organic growth in the domestic as well as International business."

Explaining the integration of the people and brands into the company's fold, Shaunak Amin, chief business development officer, said that the acquired product-mix increases the Alembic's width of therapy market participation to 55 per cent bringing into its fold premium segments. He further added that in view of the "long-term therapy" nature of those segments, which are increasingly characterized by the changing life-style of mankind, building critical mass with the Brand-franchise would be an important marketing objective for the integrated operations. Shaunak emphasized that every care was taken for seamless internalisation of the acquired Brands as well as the sales and marketing people to successfully orient to the marketing objectives through aggressive marketing-strategy, supply-chain and distribution mechanics. He expressed confidence that the acquired product-mix will perform much better under Alembic.